 | | Vol. 15.03 – 23 January, 2024 |
| |
|
|
| Using genome editing in human stem cells, scientists showed that beta cells lacking SOX9 had stunted first-phase insulin secretion.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators identified cellular rearrangements between acinar and ductal progenitors as a mechanism to drive branching morphogenesis in the pancreas while preserving the integrity of the acinar-ductal functional unit.
[Developmental Cell] |
|
|
|
| Using patient-derived iPSCs and mutated hESCs, researchers detected accumulation of misfolded proinsulin and impaired proinsulin processing in vitro, and a dominant-negative effect of these mutations on beta-cell mass and function after transplantation into mice.
[Molecular Metabolism] |
|
|
|
| The molecular aspects of taurine transport were probed by exposing the clonal pancreatic BRIN BD11 β-cells and primary mouse and human islets to a range of the homologs of the amino acid, using the hormone release and imaging of intracellular signals as surrogate read-outs.
[Acta Physiologica] |
| |
|
|
| Researchers assessed the efficacy and safety of nivolumab with modified FOLFIRINOX in metastatic pancreatic cancer. 31 treatment-naïve patients aged ≥20 years with metastatic unresectable/recurrent pancreatic cancer and Eastern Cooperative Oncology Group 0/1 score received treatment.
[BJC reports] |
|
|
|
| Scientists illustrated that tumor-derived interleukin 35 mediated the accelerated resistance of PDAC to gemcitabine (GEM). They observed that GEM resistance could spread from GEM-resistant PDAC cells to GEM-sensitive cells, and that IL-35 was responsible for the propagation of chemoresistance.
[Oncogene] |
|
|
|
| Cell growth and migration of pancreatic ductal adenocarcinoma PANC-1 cells overexpressing different eIF5A1 constructs were evaluated using crystal violet staining and transwell inserts, respectively.
[Cellular & Molecular Biology Letters] |
|
|
|
| Researchers determined if drug‑induced epigenetic reprogramming of pancreatic cancer cells affects PDAC subtype identity and chemosensitivity. Classical and basal‑like PDAC cell lines were treated for a short and long period with histone acetyltransferase and histone deacetylase inhibitors.
[Journal Of Oncology] |
|
|
|
| Investigators investigated the impact of XYA-2, a nitrogenated azaphilon previously reported from a deep-sea-derived fungus on the progression of pancreatic cancer cells.
[PeerJ] |
|
|
|
|
| The authors discuss the role of Tregs in type 1 diabetes pathogenesis and the application of Treg engineering in the context of type 1 diabetes.
[Diabetologia] |
|
|
|
| An in-depth study of the role of exosomes in the pathogenesis of diabetes may provide a novel means of diagnosing and treating diabetes. Scientists detail how exosome is involved in the development of diabetes.
[Hormones] |
|
|
|
|
| AIM ImmunoTech Inc. announced that the first subject has been enrolled at Erasmus Medical Center in a Phase Ib/II clinical trial combining AIM’s Ampligen® with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® for the treatment of late-stage pancreatic cancer.
[AIM ImmunoTech, Inc.] |
|
|
|
|
| February 14 – 16, 2024
Hinxton, England, United Kingdom |
|
|
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | Columbia University Irving Medical Center – New York, New York, United States |
|
|
|
| | Novo Nordisk – Beijing, China |
|
|
|
| | University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
| | Weill Cornell Medicine – New York City, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
